Cambridge Epigenetix

Pioneering the development of epigenetic technologies.

About

Cambridge Epigenetix (“CEGX”) is a pioneer in the development of epigenetic technologies and aims to change the way medicine is practiced by reducing several routine and important diagnostic screening tests to a simple blood draw using the 5-hydroxymethylcytosine (“5hmC”) epigenetic modification as a diagnostic biomarker. The field of epigenetics was created when colleagues of Ahren’s Science Partner, Sir Shankar Balasubramanian, showed that changes in organisms can be caused by the modification of gene expression.

Key People

Sir Shankar Balasubramanian
Joanna Holbrook
Gareth Ridge

Domain

Genetics & Platform Technologies

prev company Bicycle Therapeutics next company Graphcore

We use cookies to give you the best experience on our website. Learn more.

accept